Introduction
Standard dynamic contrast-enhanced magnetic resonance imaging (MRI) can be time-consuming, requiring approximately 5–7 min after contrast agent injection and review of approximately 2500 images by radiologists [
1]. However, its temporal resolution, typically greater than 60 s, often obscures important kinetic information of breast tumors in the early stage [
2]. In contrast, ultrafast dynamic contrast-enhanced MRI offers extremely fast temporal resolution (< 8 s), allowing for shorter scan times and better assessment of tumor kinetics [
3,
4]. Ultrafast MRI can improve lesion conspicuity by capturing cancer enhancement before background enhancement, maintaining diagnostic performance comparable to standard MRI [
5,
6]. It also provides quantitative kinetic parameters such as time to enhancement (TTE), maximum slope, and wash-in slope [
3,
7,
8]. Recent studies have demonstrated its effectiveness in predicting neoadjuvant chemotherapy response and histological factors and subtypes of breast cancer. The St. Gallen International Expert Consensus Panel recommends stratifying breast cancer patients for treatment based on their hormone receptor (HR) or human epidermal growth factor receptor 2 (HER2) status [
9]. Breast cancer treatment includes local therapies, like surgery and radiation, and systemic therapies. According to the Panel, systemic therapy is determined by subtype: luminal (HR
\(+\)), HER2-overexpressed (HR
\(-\), HER2
\(+\)), and triple-negative (HR
\(-\), HER2
\(-\)). Systemic options include endocrine therapy for HR-positive cancers, anti-HER2 therapy for HER2-positive cancers, and chemotherapy for HR- and HER2-negative cancers. Pathologic complete response after neoadjuvant chemotherapy is strongly correlated with subtype, particularly HER2-positive or triple-negative cancers. [
10,
11]. Therefore, assessing histological factors, specifically HR and HER2, as well as molecular subtypes, is essential for treatment planning and predicting therapy response.
Radiomics, extracting high-dimensional data from radiological images, provides valuable insights into tumor biology not visible to the human eye [
12]. Quantifiable features can provide systematic analysis of images by overcoming the limitations of subjective analysis and dependence on radiologists' experience in MRI interpretation [
13]. According to the radiomics quality scoring system, good radiomics studies begin with high-quality image processing, prospective design, biological correlation, and individual reader evaluation [
14]. One of main clinical roles of radiomics in breast cancer is tumor classification, and standard MRI has shown good performance in this role [
15,
16]. Radiomics approaches for classifying histological characteristics enable a noninvasive, reproducible assessment of the entire tumor. This allows for frequent reassessment through repeated imaging tests during the course of treatment. As a result, radiomics can serve as a “virtual biopsy” [
13], which is pertinent in the current era of personalized medicine.
However, only a few studies have compared the performance of ultrafast MRI and standard MRI radiomics. A pilot study by Drukker et al. [
17] reported that ultrafast MRI radiomics performed comparably to standard MRI in breast cancer diagnosis. We hypothesized that radiomics classification performance using ultrafast MRI would be similar to that using standard MRI. This prospective study aims to demonstrate the prediction performance in ultrafast MRI-derived radiomics and to compare the performance with that from standard MRI-derived radiomics, in determining histological factors and subtypes in invasive breast cancer. Additionally, the impact of tumor masks from radiologists with different seniority was also elaborated.
Discussion
Our prospective radiomics study demonstrates that ultrafast MRI exhibits superior classification performance for breast cancer HER2 status and molecular subtype compared to standard MRI for radiologists of different experience levels (a dedicated breast radiologist and a radiology resident). Notably, ultrafast MRI outperformed standard MRI in predicting all subtypes including luminal, HER2-overexpressed, and triple-negative. Additionally, both readers showed high agreement for tumor segmentation in both MRI modalities, as indicated by Dice and Jaccard similarity coefficients. Consequently, our study underscores the potential clinical utility of ultrafast MRI radiomics in breast cancer classification, irrespective of readers' experience levels.
Ultrafast MRI is taken with high temporal resolution and completed before the initial postcontrast images of a standard dynamic MRI begin. Previous studies have validated its use in accurate evaluation of tumor size with good lesion conspicuity [
5,
6]. Furthermore, ultrafast MRI produces reproducible quantitative kinetic features [
21,
35]. In this study, TTE was most frequently selected as a radiomics signature among four kinetic features to classify HR and HER2 status and luminal and triple-negative subtypes. TTE indicates the time interval between when the tumor begins to enhance and when the aorta begins to enhance. Previous studies have shown that shorter TTE is valuable to differentiate malignant from benign breast lesions and correlates with tumor aggressiveness, high grade, HR negativity, HER2 positivity, and triple-negative subtype [
21,
36‐
38]. Therefore, our results are consistent with previous studies.
On standard MRI, the association between HER2 status and radiomics, as well as the relationship between molecular subtypes and radiomics, has been reported [
39‐
42]. This year, Ramtohul et al. [
39] demonstrated high performance (AUC [95% CI] = 0.80 [0.71–0.89]) in differentiating HER2-zero cancers vs HER2-low and positive cancers. In recent studies on the prediction of triple-negative cancers, reported AUC values ranged from 0.73 to 0.88 in radiomics models using standard MRI [
41,
42]. Apart from luminal subtypes, which tend to respond well to endocrine therapy, HER2 overexpression causes uncontrolled cell growth and is associated with higher recurrence and mortality in the absence of targeted therapy [
43], while triple-negative breast cancers can result in the worst prognosis as they can only be treated with chemotherapy and radiotherapy. Therefore, our findings that ultrafast MRI outperforms standard MRI in classifying HER2 status and all molecular subtypes raise expectations for the clinical applicability of ultrafast MRI radiomics in breast cancer.
In radiomics, agreement on tumor segmentation among various readers is important to increase reproducibility and generalizability. Granzier et al. [
44] evaluated segmentation variability among four readers with different breast imaging experiences (a dedicated breast radiologist, a radiology resident, a medical student, and a PhD. candidate) and observed a Dice similarity coefficient of 0.81, indicating a good spatial overlap regardless of different expertise. In our study, the Dice similarity coefficients of ultrafast MRI (0.91) and standard MRI (0.92) were higher than that of the previous study [
44]. Due to the high agreement on tumor segmentation between the two readers in our study, the selected radiomic signatures for both readers were similar. For instance, when classifying histological factors, the majority of radiomic signatures consisted of first-order features on ultrafast MRI and GLCM features on standard MRI for both readers. High segmentation agreement between various MRI readers increases the robustness of radiomics and improves the reproducibility and generalizability of artificial intelligence-assisted interpretation.
Our prospective study contributes to the field of breast cancer radiomics and ultrafast MRI research. First, there are a few reports applying radiomics to ultrafast MRI and our radiomics results demonstrate that ultrafast MRI can be an alternative to the standard MRI in breast oncology imaging. Second, we evaluated breast cancer classification performance for all molecular subtypes and demonstrated superior performance compared to standard MRI. Third, we designed a high-quality radiomics study to obtain robust radiomics results. Our radiomics quality score was high, 69% (25/36), due to prospective study design, segmentation by different readers, and open-source analyzing software [
14,
26]. A previous study reported the mean radiomics quality score of oncology imaging of 26% (9/36) [
14].
Our study has some limitations. First, we did not evaluate the impact of individual MRI characteristics, such as tumor size or morphological features, on classification performance. For example, the tumor sizes in this study ranged from 6 to 115 mm, showing considerable variability. Predicting performance evaluation according to the size subcategory would be necessary for clinical implementation. Second, we did not include cancers smaller than 6 mm in size or inflammatory cancers. Inflammatory breast cancer involves the skin and dermal lymphatics, making it challenging to delineate tumor margins. A previous study demonstrates that “easy tumors,” defined as homogenous, round tumors with relatively sharp margins have better agreement than “challenging tumors” that do not meet these criteria [
44]. To improve the clinical utility of ultrafast MRI radiomics for breast cancer classification, further research on the impact of various lesion characteristics should be conducted using a larger population, including tumors of various morphologies and sizes.
In conclusion, ultrafast MRI-based radiomics can serve as a noninvasive tool to classify breast cancer according to histological factors and subtypes as compared with standard MRI. Ultrafast MRI exhibited superior performance to standard MRI in classifying HER2 status, as well as luminal, HER2-overexpressed, and triple-negative molecular subtypes. These results are consistent regardless of the experience of the radiologists. Our study demonstrates the promise of radiomics approaches with ultrafast MRI that have advantages in terms of scan time and lesion conspicuity, which are problems with standard MRI.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.